Study of N297A: A Mouse Antibody for Treating Autoimmune Diseases
Author Information
Author(s): Debra T. Chao, M. Xiaohong Li, Olga Park, Hyunjoo Law, Debbie
Primary Institution: PDL BioPharma, Inc.
Hypothesis
Can the Fc-modified anti-mouse CD3 antibody N297A effectively model the mechanisms of action of Fc-modified anti-human CD3 antibodies?
Conclusion
N297A shows promise in reducing body weight loss in a murine model of colitis and shares functional characteristics with anti-human CD3 antibodies.
Supporting Evidence
- N297A significantly reduced body weight loss in a murine model of colitis.
- N297A exhibited similar biological effects as Fc-modified anti-human CD3 antibodies.
- N297A treatment led to a transient reduction in blood lymphocyte counts.
- N297A induced lower levels of cytokines compared to the wild-type antibody.
- N297A preferentially modulated activated T cells over resting T cells.
Takeaway
Researchers created a special mouse antibody that helps treat diseases by reducing harmful immune responses, and it works similarly to a human antibody.
Methodology
The study involved generating an Fc-modified anti-mouse CD3 antibody and testing its effects in vitro and in vivo using various mouse models.
Potential Biases
Potential bias in interpreting results due to the use of animal models.
Limitations
The study primarily focused on mouse models, which may not fully replicate human responses.
Participant Demographics
Mice used included BALB/c, C57/B6, and IL-10 deficient strains.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website